Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Fredericksburg Oncology has started recruiting patients in a Phase II randomised trial of the chemotherapy medications Carboplatin, Paclitaxel and Bevacizumab, with or without the drug Everolimus.
Subscribe to our email newsletter
Fredericksburg said that the trial, supported by the National Cancer Institute (NCI) to evaluate treatment for metastatic (advanced stage) melanoma, is expected to enroll 148 patients across the country.
The current trial, designed at the Mayo Clinic, combines chemotherapy with targeted molecular agents in an effort to improve control of this difficult disease, reports Frederick Tucker, who heads the practice.
According to the Clinical Research Nurse, Brenda McClafferty, the drugs are FDA approved to treat some other cancers, but their use for metastatic malignant melanoma is considered investigational.
Ms McClafferty said: “Such trials help us find the most effective doses, monitor side effects and evaluate the efficacy of new treatments. In the case of melanoma, we are still at the starting lines, and we need clinical trials to find treatments that will truly make a difference.”